Marker Therapeutics ( (MRKR) ) has released its Q1 earnings. Here is a breakdown of the information Marker Therapeutics presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing novel T cell-based immunotherapies for treating hematological malignancies and solid tumors. The company recently released its earnings report for the first quarter of 2025, highlighting a challenging period with a significant net loss. The report indicates a decrease in grant income and an increase in operating expenses, leading to a net loss of $4.4 million for the quarter. The company’s cash and cash equivalents decreased from $19.2 million at the end of 2024 to $13.7 million by March 31, 2025. Marker Therapeutics continues to rely on grant funding to support its research and development activities, with several grants received from institutions like CPRIT, FDA, and NIH. The company is actively seeking additional financing and grant opportunities to extend its operational runway beyond the first quarter of 2026. Looking ahead, Marker Therapeutics plans to continue its clinical trials and explore strategic partnerships to advance its product candidates towards commercialization.